Life Sciences Commons^™

Protection From Staphylococcus Aureus Bloodstream Infection By Probiotic Exopolysaccharide, Wonbeom Paik

Dissertations

Staphylococcus aureus is known to cause severe systemic infection with high mortality rates. Antibiotics are the only approved therapy for patients, but the widespread prevalence of antibiotic resistant strains limits treatment efficacy, and many patients succumb to the disease. Many probiotic agents are commercially available, but the mechanisms by which they benefit are not known. Understanding these mechanisms will help develop novel therapeutics that can improve healthcare, including systemic infections by S. aureus. Bacillus subtilis is a probiotic bacterium that produces an exopolysaccharide (EPS) that induces anti inflammatory macrophages (MΦ). We tested if EPS could be used for systemic S. …

Characterization Of Exopolysaccharide (Eps) Produced By Bacillus Subtilis Mutants, Alexander Argianas

Master's Theses

Bacillus subtilis is a probiotic bacterium that can protect against the murine-

specific attaching and effacing (A/E) pathogen Citrobacter rodentium. C. rodentium displays many features observed with the human pathogen enteropathogenic E. coli (EPEC). Protection by B. subtilis is mediated by exopolysaccharide (EPS), which is encoded by the epsA-O operon that contains 15 genes. Disruption of one of these genes, epsH, which appears to encode a putative glycosyltransferase, leads to the loss of protective capacity by B. subtilis and by EPS. EPS is a major component of the B. subtilis biofilm and the ΔepsH mutant is unable to form a …